| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.
|
J Clin Endocrinol Metab
|
2009
|
2.50
|
|
2
|
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
|
Am Heart J
|
2004
|
2.09
|
|
3
|
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?
|
Metabolism
|
2006
|
2.01
|
|
4
|
Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study.
|
Diabetes Care
|
2003
|
1.79
|
|
5
|
CORONA, statins, and heart failure: who lost the crown?
|
Angiology
|
2008
|
1.38
|
|
6
|
Pheochromocytoma: an update on genetics and management.
|
Endocr Relat Cancer
|
2007
|
1.34
|
|
7
|
Adrenal incidentaloma: a diagnostic challenge.
|
Hormones (Athens)
|
2009
|
1.29
|
|
8
|
Hyperuricemia as a risk factor for cardiovascular disease.
|
Expert Rev Cardiovasc Ther
|
2014
|
1.11
|
|
9
|
Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".
|
Dig Liver Dis
|
2012
|
1.06
|
|
10
|
Metabolic syndrome in clinical practice.
|
Cardiol J
|
2014
|
1.06
|
|
11
|
Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention.
|
Circ J
|
2013
|
1.06
|
|
12
|
Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
|
Expert Opin Pharmacother
|
2008
|
1.00
|
|
13
|
Dyslipidemia as a risk factor for ischemic stroke.
|
Curr Top Med Chem
|
2009
|
0.99
|
|
14
|
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
|
Curr Vasc Pharmacol
|
2006
|
0.99
|
|
15
|
Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk?
|
Curr Vasc Pharmacol
|
2010
|
0.95
|
|
16
|
Triglycerides and vascular risk: insights from epidemiological data and interventional studies.
|
Curr Drug Targets
|
2009
|
0.95
|
|
17
|
Statin discontinuation: an underestimated risk?
|
Curr Med Res Opin
|
2008
|
0.95
|
|
18
|
Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?
|
Curr Vasc Pharmacol
|
2011
|
0.94
|
|
19
|
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
|
Expert Opin Pharmacother
|
2007
|
0.93
|
|
20
|
Hyperuricaemia: more than just a cause of gout?
|
J Cardiovasc Med (Hagerstown)
|
2013
|
0.92
|
|
21
|
Lipoprotein a: where are we now?
|
Curr Opin Cardiol
|
2009
|
0.92
|
|
22
|
Lipid-lowering agents and new onset diabetes mellitus.
|
Expert Opin Pharmacother
|
2010
|
0.90
|
|
23
|
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
|
Metabolism
|
2012
|
0.89
|
|
24
|
Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures.
|
Curr Drug Targets
|
2007
|
0.89
|
|
25
|
The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
|
J Clin Pharmacol
|
2007
|
0.88
|
|
26
|
Atherogenesis in renal patients: a model of vascular disease?
|
Curr Vasc Pharmacol
|
2008
|
0.87
|
|
27
|
Anti-inflammatory effects of fibrates: an overview.
|
Curr Med Chem
|
2009
|
0.86
|
|
28
|
Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?
|
Ann Med
|
2011
|
0.86
|
|
29
|
Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy.
|
J Diabetes Complications
|
2006
|
0.85
|
|
30
|
Has the time come for a new definition of microalbuminuria?
|
Curr Vasc Pharmacol
|
2008
|
0.85
|
|
31
|
Implementation of guidelines for the management of arterial hypertension. The impulsion study.
|
Open Cardiovasc Med J
|
2009
|
0.85
|
|
32
|
Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes.
|
Angiology
|
2006
|
0.84
|
|
33
|
Statins and renal function. Is the compound and dose making a difference?
|
Nephrol Dial Transplant
|
2007
|
0.84
|
|
34
|
The role of statins for the primary and secondary prevention of coronary heart disease in women.
|
Curr Pharm Des
|
2009
|
0.84
|
|
35
|
The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification.
|
Curr Opin Cardiol
|
2010
|
0.84
|
|
36
|
The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis.
|
Curr Vasc Pharmacol
|
2010
|
0.84
|
|
37
|
The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
|
Expert Opin Ther Targets
|
2007
|
0.83
|
|
38
|
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
|
Expert Opin Drug Metab Toxicol
|
2014
|
0.83
|
|
39
|
Impact of statins on glucose metabolism--a matter of debate.
|
Am J Cardiol
|
2011
|
0.83
|
|
40
|
Metabolic syndrome and non-cardiac vascular diseases: an update from human studies.
|
Curr Pharm Des
|
2014
|
0.83
|
|
41
|
Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.
|
Int J Nanomedicine
|
2006
|
0.82
|
|
42
|
Statins and heart failure.
|
J Am Coll Cardiol
|
2010
|
0.82
|
|
43
|
Omega-3 fatty acids: how can they be used in secondary prevention?
|
Curr Atheroscler Rep
|
2008
|
0.81
|
|
44
|
Endothelial function, arterial stiffness and lipid lowering drugs.
|
Expert Opin Ther Targets
|
2007
|
0.81
|
|
45
|
Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview.
|
Curr Vasc Pharmacol
|
2014
|
0.81
|
|
46
|
Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?
|
Curr Vasc Pharmacol
|
2010
|
0.81
|
|
47
|
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
|
Kidney Int
|
2004
|
0.80
|
|
48
|
Lipid lowering agents and the endothelium: an update after 4 years.
|
Curr Vasc Pharmacol
|
2012
|
0.80
|
|
49
|
Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.
|
Dig Dis Sci
|
2012
|
0.80
|
|
50
|
Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.
|
Curr Vasc Pharmacol
|
2014
|
0.80
|
|
51
|
Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients.
|
Curr Med Res Opin
|
2003
|
0.80
|
|
52
|
Should we consider Addison's disease in the differential diagnosis of persistent hypertransaminasemia? A case report.
|
Acta Gastroenterol Belg
|
2011
|
0.80
|
|
53
|
Dry cough as first manifestation of giant-cell arteritis.
|
J Am Geriatr Soc
|
2006
|
0.80
|
|
54
|
Colesevelam: a new and improved bile acid sequestrant?
|
Curr Pharm Des
|
2013
|
0.79
|
|
55
|
Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics.
|
Am J Cardiovasc Drugs
|
2012
|
0.79
|
|
56
|
Preventing macrovascular complications of diabetes: where do we stand with glycemic control?
|
Expert Opin Investig Drugs
|
2008
|
0.79
|
|
57
|
Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
|
Expert Opin Investig Drugs
|
2008
|
0.79
|
|
58
|
Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review.
|
Angiology
|
2013
|
0.79
|
|
59
|
Statins in patients with renal dysfunction.
|
Am J Cardiol
|
2012
|
0.79
|
|
60
|
Effect of apolipoprotein E polymorphism on serum uric acid levels in healthy subjects.
|
J Investig Med
|
2005
|
0.79
|
|
61
|
The effect of cholesterol-lowering treatment on renal function.
|
Am J Kidney Dis
|
2006
|
0.79
|
|
62
|
Statin potency, LDL receptors and new onset diabetes.
|
Curr Vasc Pharmacol
|
2014
|
0.78
|
|
63
|
Endocrine hypertension: diagnosis and management of a complex clinical entity.
|
Curr Vasc Pharmacol
|
2010
|
0.78
|
|
64
|
JUPITER: major implications for vascular risk assessment.
|
Curr Med Res Opin
|
2009
|
0.78
|
|
65
|
To switch (statins) or not to switch? That is the question.
|
Expert Opin Pharmacother
|
2010
|
0.78
|
|
66
|
Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus.
|
Nat Clin Pract Endocrinol Metab
|
2008
|
0.78
|
|
67
|
Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?
|
Curr Pharm Des
|
2007
|
0.78
|
|
68
|
Is the risk for cardiovascular disease increased in all phenotypes of the polycystic ovary syndrome?
|
Angiology
|
2011
|
0.78
|
|
69
|
Stage of chronic kidney disease and severity of coronary heart disease manifestation.
|
Expert Opin Pharmacother
|
2012
|
0.78
|
|
70
|
Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?
|
Expert Opin Ther Targets
|
2008
|
0.78
|
|
71
|
Ezetimibe therapy for dyslipidemia: an update.
|
Curr Pharm Des
|
2013
|
0.78
|
|
72
|
Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease.
|
Curr Pharm Des
|
2014
|
0.78
|
|
73
|
Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients.
|
Neurol Res
|
2010
|
0.77
|
|
74
|
Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.
|
Expert Opin Ther Targets
|
2013
|
0.77
|
|
75
|
Management of statin-intolerant high-risk patients.
|
Curr Vasc Pharmacol
|
2010
|
0.77
|
|
76
|
Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.
|
Curr Vasc Pharmacol
|
2009
|
0.77
|
|
77
|
Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance.
|
Circ J
|
2011
|
0.77
|
|
78
|
Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas.
|
Endocr Relat Cancer
|
2008
|
0.77
|
|
79
|
Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?
|
Open Cardiovasc Med J
|
2012
|
0.77
|
|
80
|
Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial.
|
J Hepatol
|
2012
|
0.77
|
|
81
|
Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia.
|
Atherosclerosis
|
2002
|
0.77
|
|
82
|
Multifactorial intervention for the prevention of vascular complications of type 2 diabetes.
|
Hellenic J Cardiol
|
2009
|
0.76
|
|
83
|
Current treatment for nonalcoholic fatty liver disease.
|
Expert Opin Pharmacother
|
2011
|
0.76
|
|
84
|
High density lipoprotein cholesterol and statin trials.
|
Curr Med Chem
|
2008
|
0.76
|
|
85
|
Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome.
|
Expert Opin Pharmacother
|
2012
|
0.76
|
|
86
|
Residual cardiac risk reduction beyond lipid lowering.
|
Hellenic J Cardiol
|
2011
|
0.76
|
|
87
|
Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment.
|
Atherosclerosis
|
2003
|
0.76
|
|
88
|
Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk.
|
Angiology
|
2012
|
0.76
|
|
89
|
Effect of antihypertensive drug-associated diabetes on cardiovascular risk.
|
Hellenic J Cardiol
|
2010
|
0.76
|
|
90
|
PCI and stable coronary heart disease--COURAGE to change our minds?
|
Curr Vasc Pharmacol
|
2007
|
0.76
|
|
91
|
The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?
|
Hellenic J Cardiol
|
2009
|
0.76
|
|
92
|
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
|
Clin Cardiol
|
2009
|
0.76
|
|
93
|
Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?
|
Angiology
|
2008
|
0.76
|
|
94
|
Metabolic syndrome and arterial stiffness: the past, the present and the future.
|
J Cardiovasc Med (Hagerstown)
|
2013
|
0.76
|
|
95
|
Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertension.
|
Curr Vasc Pharmacol
|
2012
|
0.76
|
|
96
|
Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'.
|
Clin Cardiol
|
2012
|
0.76
|
|
97
|
The role of statins in the treatment of type 2 diabetes mellitus: an update.
|
Curr Pharm Des
|
2014
|
0.76
|
|
98
|
Statins and nonalcoholic fatty liver disease: a bright future?
|
Expert Opin Investig Drugs
|
2013
|
0.76
|
|
99
|
Lipid-lowering therapy in patients with peripheral arterial disease.
|
J Cardiovasc Pharmacol Ther
|
2005
|
0.76
|
|
100
|
Statin-fibrate combination for mixed dyslipidaemia: a limited option?
|
Curr Med Res Opin
|
2010
|
0.76
|
|
101
|
Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases.
|
Open Cardiovasc Med J
|
2011
|
0.75
|
|
102
|
Statins and regression of coronary atherosclerosis.
|
JAMA
|
2007
|
0.75
|
|
103
|
New-onset diabetes after transplantation.
|
Lancet
|
2005
|
0.75
|
|
104
|
Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention.
|
Curr Med Res Opin
|
2013
|
0.75
|
|
105
|
Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
|
Am J Cardiol
|
2008
|
0.75
|
|
106
|
Alcohol consumption and the heart.
|
Int J Cardiol
|
2013
|
0.75
|
|
107
|
Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.
|
Oman Med J
|
2012
|
0.75
|
|
108
|
Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study.
|
Clin Appl Thromb Hemost
|
2012
|
0.75
|
|
109
|
Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome.
|
Curr Pharm Des
|
2014
|
0.75
|
|
110
|
Therapeutic options for statin-intolerant patients.
|
Curr Med Res Opin
|
2012
|
0.75
|
|
111
|
Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity.
|
J Clin Lipidol
|
2012
|
0.75
|
|
112
|
Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
|
J Clin Lipidol
|
2011
|
0.75
|
|
113
|
Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs.
|
Curr Vasc Pharmacol
|
2016
|
0.75
|
|
114
|
Reaching hypertriglyceridemia goals.
|
Curr Med Res Opin
|
2013
|
0.75
|
|
115
|
Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit.
|
Expert Rev Cardiovasc Ther
|
2014
|
0.75
|
|
116
|
Is there any association between adiponectin gene polymorphisms and cardiovascular disease?
|
Angiology
|
2012
|
0.75
|
|
117
|
Gender disparity in lipid target achievements in high and very high atherosclerotic cardiovascular disease risk patients in the Arabian Gulf.
|
Curr Vasc Pharmacol
|
2016
|
0.75
|
|
118
|
Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).
|
Curr Vasc Pharmacol
|
2014
|
0.75
|
|
119
|
Hypertrophic Mesenteric Adipose Tissue May Play a Role in Atherogenesis in Inflammatory Bowel Diseases.
|
Inflamm Bowel Dis
|
2016
|
0.75
|
|
120
|
Psoriasis and Vascular Risk : An Update.
|
Curr Pharm Des
|
2014
|
0.75
|
|
121
|
Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
|
Curr Med Res Opin
|
2013
|
0.75
|
|
122
|
Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
|
Curr Vasc Pharmacol
|
2016
|
0.75
|
|
123
|
Atherosclerotic renal artery stenosis: an update on diagnosis and management.
|
Curr Vasc Pharmacol
|
2011
|
0.75
|
|
124
|
Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?
|
Angiology
|
2009
|
0.75
|
|
125
|
Current challenges in antihypertensive treatment in the elderly.
|
Pol Arch Med Wewn
|
2016
|
0.75
|
|
126
|
Unusual manifestation of diarrhea-associated haemolytic uraemic syndrome in an adult.
|
Ren Fail
|
2008
|
0.75
|
|
127
|
Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?
|
Expert Opin Investig Drugs
|
2008
|
0.75
|
|
128
|
Achieving lipid targets in primary care settings.
|
Curr Med Res Opin
|
2014
|
0.75
|
|
129
|
Does metabolic syndrome influence outcome following percutaneous coronary intervention?
|
Angiology
|
2011
|
0.75
|
|
130
|
Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.
|
Am J Cardiol
|
2012
|
0.75
|
|
131
|
The interplay between TSH and lipids. what should clinicians know?
|
Curr Vasc Pharmacol
|
2015
|
0.75
|
|
132
|
Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?
|
Expert Opin Pharmacother
|
2008
|
0.75
|
|
133
|
Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors.
|
Curr Pharm Des
|
2014
|
0.75
|
|
134
|
Should atenolol still be recommended as first-line therapy for primary hypertension?
|
Hellenic J Cardiol
|
2006
|
0.75
|
|
135
|
Editorial: (Persistent elevation of blood pressure in children and adolescents is associated with arterial hypertension and premature atherosclerosis in adults. Is it possible to reverse this?).
|
Curr Vasc Pharmacol
|
2014
|
0.75
|
|
136
|
Should we expand the concept of coronary heart disease equivalents?
|
Curr Opin Cardiol
|
2014
|
0.75
|
|
137
|
Targets for low-density lipoprotein cholesterol levels in patients with stable coronary heart disease: where are we now after the "treating to new targets" (TNT) trial?
|
Hellenic J Cardiol
|
2005
|
0.75
|
|
138
|
The DEFINE study: a bright future for CETP inhibitors?
|
Expert Opin Investig Drugs
|
2011
|
0.75
|
|
139
|
Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is coming soon; let us combine them all.
|
Curr Pharm Des
|
2014
|
0.75
|
|
140
|
Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.
|
Curr Pharm Des
|
2016
|
0.75
|
|
141
|
Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
|
Curr Vasc Pharmacol
|
2016
|
0.75
|